Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this trial is to assess the effect of immunotherapy with the bacterial preparation MV130 on the spread and course of SARS-CoV-2 infection in highly exposed subjets, as is the case with healthcare personnel.
Description: Incidence of subjects with COVID-19, defined by the presence of: Fever Any of the respiratory signs and/or symptoms: cough, dyspnea, respiratory failure, runny nose/nasal obstruction. Positive test for SARS-COV-2 (PCR o serology)
Measure: Incidence of subjects with COVID-19 Time: 60 daysDescription: Incidence of severe COVID-19, defined by CURB > 2 and/or death
Measure: Severity of COVID-19 Time: 60 daysDescription: Rate of subjects with seroconversion to SARS-CoV-2 (negative serology at the beginning of the study and positive at the end of the study
Measure: Seroconversion to SARS-CoV-2 Time: 60 daysDescription: Rate of subjects with any symptoms, whether confirmed, probable or suspected, according to the WHO definition
Measure: Subjects with symptoms Time: 60 daysDescription: The effect of the treatment on the severity of the disease will be measured based on the rate of subjects requiring hospital admission for COVID-19
Measure: Hospital admission due to COVID-19 Time: 60 daysDescription: The effect of the treatment on the severity of the disease will be measured based on the rate of subjects who require admission to an intensive care unit for COVID-19 • Time from confirmation of SARS-CoV-2 infection to the appearance of symptoms.
Measure: Admission to an intensive care unit due to COVID-19 Time: 60 daysDescription: Elapsed time until the first symptoms of COVID-19 appears to hospitalization due to COVID-19.
Measure: Elapsed time until hospitalization Time: 60 daysDescription: Elapsed time until the first symptoms of COVID-19 appears to admission into an intensive care unit pro COVID-19.
Measure: Elapsed time until admission into an care unit for COVID-19 Time: 60 daysDescription: Elapsed time until the first symptoms of COVID-19 appears to death from any cause not related to COVID-19.
Measure: Elapsed time until death not related to COVID-19 Time: 60 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports